BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35254954)

  • 1. Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery.
    Rachmale M; Rajput N; Jadav T; Sahu AK; Tekade RK; Sengupta P
    Drug Metab Rev; 2022 May; 54(2):101-119. PubMed ID: 35254954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenobiotic Nuclear Receptors Pregnane X Receptor and Constitutive Androstane Receptor Regulate Antiretroviral Drug Efflux Transporters at the Blood-Testis Barrier.
    Whyte-Allman SK; Hoque MT; Jenabian MA; Routy JP; Bendayan R
    J Pharmacol Exp Ther; 2017 Dec; 363(3):324-335. PubMed ID: 28970358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
    Bhagyaraj E; Ahuja N; Kumar S; Tiwari D; Gupta S; Nanduri R; Gupta P
    Cell Cycle; 2019 Dec; 18(24):3589-3602. PubMed ID: 31739702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-specific effects of excipients on oral drug bioavailability.
    Mai Y; Madla CM; Shao H; Qin Y; Merchant HA; Murdan S; Basit AW
    Int J Pharm; 2022 Dec; 629():122365. PubMed ID: 36336203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
    Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
    Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier.
    Narang VS; Fraga C; Kumar N; Shen J; Throm S; Stewart CF; Waters CM
    Am J Physiol Cell Physiol; 2008 Aug; 295(2):C440-50. PubMed ID: 18524938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes.
    Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
    Curr Pharm Des; 2013; 19(40):7126-40. PubMed ID: 23829373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
    Shi W; Zhang P; Zou F; Zhou J; Yin Z; Cai Z; Ghaleb H; Jiang Y; Huang W; Liu Y; Qiu Q; Qian H
    Eur J Med Chem; 2022 Apr; 233():114231. PubMed ID: 35247755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of safety and efficacy of anti-cancer chemotherapeutics by tailoring their site-specific intracellular bioavailability through transporter modulation.
    Dhakne P; Pillai M; Mishra S; Chatterjee B; Tekade RK; Sengupta P
    Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188906. PubMed ID: 37172652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
    Ambjørner SEB; Wiese M; Köhler SC; Svindt J; Lund XL; Gajhede M; Saaby L; Brodin B; Rump S; Weigt H; Brünner N; Stenvang J
    Cells; 2020 Mar; 9(3):. PubMed ID: 32143347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line.
    Harmsen S; Meijerman I; Febus CL; Maas-Bakker RF; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):765-71. PubMed ID: 20041327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.
    Albermann N; Schmitz-Winnenthal FH; Z'graggen K; Volk C; Hoffmann MM; Haefeli WE; Weiss J
    Biochem Pharmacol; 2005 Sep; 70(6):949-58. PubMed ID: 16054595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
    Weiss J; Becker JP; Haefeli WE
    Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.